Background: The association between the apolipoprotein E (APOE) ɛ4 allele and high risk of developing Alzheimer’s disease (AD) dementia before the age of 80 has been recognized for over 30 years. However, the timing and mode of action of APOE is not understood, nor has there been a detailed analysis of the effect of APOE genotype on memory, hippocampal volume, and amyloid-β (Aβ) levels in cognitively normal adults.
Objective: Examine the effect of APOE allelic genotype on the relationship between Aβ levels, hippocampal volume, and memory in cognitively normal adults.
Methods: This is a cross-sectional study of 989 cognitively normal older adults enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, all of whom underwent APOE genotyping and memory assessment. A subset of this group underwent PET neuroimaging for Aβ (n = 585) and MRI for hippocampal volume (n = 303).
Results:APOEɛ4 homozygotes (ɛ4/ɛ4) showed significantly worse episodic memory and higher Aβ levels than ɛ4 heterozygotes. The relationship between increasing Aβ levels and worse episodic memory was significant for ɛ3 homozygotes (ɛ3/ɛ3), ɛ4 heterozygotes, and strongest for ɛ4 homozygotes. There were no differences in hippocampal volume between APOE groups; the relationship between smaller hippocampal volume and worse episodic memory was significant only for ɛ4 homozygotes.
Conclusion:APOE acts in a co-dominant fashion on Aβ levels, episodic memory, and hippocampal volume in cognitively normal older adults. APOEɛ4 is central to the events that lead to AD in cognitively normal older adults, likely through a quantitative role in the disruption of Aβ clearance.
RosesAD (2006) On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis9, 361–366.
2.
CaselliRJ, DueckAC, OsborneD, SabbaghMN, ConnorDJ, AhernGL, BaxterLC, RapcsakSZ, ShiJ, WoodruffBK, LockeDEC, SnyderCH, AlexanderGE, RademakersR, ReimanEM (2009) Longitudinal modeling of age-related memory decline and the APOE ɛ4 effect. New Engl J Med361, 255–263.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. J Amer Med Assoc278, 1349–1356.
5.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
6.
OssenkoppeleR, JansenWJ, RabinoviciGD, KnolDL, van der FlierWM, van BerckelBN, ScheltensP, VisserPJ, GroupAPS, VerfaillieSC, ZwanMD, AdriaanseSM, LammertsmaAA, BarkhofF, JagustWJ, MillerBL, RosenHJ, LandauSM, VillemagneVL, RoweCC, LeeDY, NaDL, SeoSW, SarazinM, RoeCM, SabriO, BarthelH, KoglinN, HodgesJ, LeytonCE, VandenbergheR, van LaereK, DrzezgaA, ForsterS, GrimmerT, Sánchez-JuanP, CarrilJM, MokV, CamusV, KlunkWE, CohenAD, MeyerPT, HellwigS, NewbergA, FrederiksenKS, FleisherAS, MintunMA, WolkDA, NordbergA, RinneJO, ChételatG, LleoA, BlesaR, ForteaJ, MadsenK, RodrigueKM, BrooksDJ (2015) Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis. J Amer Med Assoc313, 1939–1949.
7.
RoweCC, EllisKA, RimajovaM, BourgeatP, PikeKE, JonesG, FrippJ, Tochon-DanguyH, MorandeauL, O’KeefeG, PriceR, RanigaP, RobinsP, AcostaO, LenzoN, SzoekeC, SalvadoO, HeadR, MartinsR, MastersCL, AmesD, VillemagneV (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging31, 1275–1283.
8.
PetersenRC, WisteHJ, WeigandSD, RoccaWA, RobertsRO, MielkeMM, LoweVJ, KnopmanDS, PankratzVS, MachuldaMM, GedaYE, JackCRJ (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol73, 85–92.
9.
LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
10.
YuJT, TanL, HardyJ (2014) Apolipoprotein E in Alzheimer’s disease: An update. Ann Rev Neuroscl37, 79.
11.
LimYY, EllisKA, AmesD, DarbyD, HarringtonK, MartinsRN, MastersCL, RoweC, SavageG, SzoekeC, VillemagneVL, MaruffP, AIBL Research Group (2013) Aβ amyloid, cognition and APOE genotype in healthy older adults. Alzheimers Dement9, 538–545.
12.
KantarciK, LoweV, PrzybelskiSA, WeigandSD, SenjemML, IvnikRJ, PreboskeGM, RobertsR, GedaYE, BoeveBF, KnopmanDS, PetersenRC, JackCR (2012) APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology78, 232–240.
13.
EllisKA, BushAI, DarbyD, De FazioD, FosterJ, HudsonP, LautenschlagerNT, LenzoN, MartinsRN, MaruffP, MastersC, MilnerA, PikeK, RoweC, SavageG, SzoekeC, TaddeiK, VillemagneV, WoodwardM, AmesD, AIBL Research Group (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr21, 672–687.
14.
WongDF, RosenbergPB, ZhouY, KumarA, RaymontV, RavertHT, DannalsRF, NandiA, BrasićJR, YeW, HiltonJ, LyketsosC, KungHF, JoshiAD, SkovronskyDM, PontecorvoMJ (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med51, 913–920.
15.
VandenbergheR, Van LaereK, IvanoiuA, SalmonE, BastinC, TriauE, HasselbalchS, LawI, AndersenA, KornerA, MinthonL, GarrauxG, NelissenN, BormansG, BuckleyC, OweniusR, ThurfjellL, FarrarG, BrooksDJ (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol68, 319–329.
16.
ClarkCM, SchneiderJA, BedellBJ, BeachTG, BilkerWB, MintunMA, PontecorvoMJ, HeftiF, CarpenterAP, FlitterML, KrautkramerMJ, KungHF, ColemanRE, DoraiswamyPM, FleisherAS, SabbaghMN, SadowskyCH, ReimanEP, ZehntnerSP, SkovronskyDM, AV45-A07 Study Group (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. J Amer Med Assoc305, 275–283.
CollinsDL, ZijdenbosAP, KollokianV, SledJG, KabaniNJ, HolmesCJ, EvansAC (1998) Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging17, 463–468.
19.
AcostaO, BourgeatP, ZuluagaMA, FrippJ, SalvadoO, OurselinS, Alzheimer’s Disease Neuroimaging Initiative (2009) Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Med Image Anal13, 730–743.
20.
BoccardiM, BocchettaM, ApostolovaLG, BarnesJ, BartzokisG, CorbettaG, DeCarliC, deToledo-MorrellL, FirbankM, GanzolaR, GerritsenL, HennemanW, KillianyRJ, MalykhinN, PasqualettiP, PruessnerJC, RedolfiA, RobitailleN, SoininenH, TolomeoD, WangL, WatsonC, WolfH, DuvernoyH, DuchesneS, JackCR, FrisoniGB, EADC-ADNI Working Group on the Harmonized Protocol for Manual Hippocampal Segmentation (2015) Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimers Dement11, 126–138.
21.
LimYY, MaruffP, PietrzakRH, AmesD, EllisKA, HarringtonK, LautenschlagerNT, SzoekeC, MartinsRN, MastersCL, VillemagneVL, RoweCC, AIBL Research Group (2014) Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain137, 221–231.
22.
RoweCC, AckermannU, BrowneW, MulliganR, PikeKL, O’KeefeG, Tochon-DanguyH, ChanG, BerlangieriSU, JonesG, Dickinson-RoweKL, KungHP, ZhangW, KungMP, SkovronskyD, DyrksT, HollG, KrauseS, FriebeM, LehmanL, LindemannS, DinkelborgLM, MastersCL, VillemagneVL (2008) Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol7, 129–135.
23.
ThaiC, LimYY, VillemagneVL, LawsSM, AmesD, EllisKA, Rainey-SmithSR, MartinsRN, MastersCL, RoweCC, MaruffP, AIBL Research Group (2015) Amyloid-related memory decline in preclinical Alzheimer’s disease is dependent on APOE ɛ4 and is detectable over 18-months. PLoS One10, e0139082.
24.
VillemagneVL, PikeKE, ChételatG, EllisKA, MulliganRS, BourgeatP, AckermannU, JonesG, SzoekeC, SalvadoO, MartinsR, O’KeefeG, MathisCA, KlunkWE, AmesD, MastersCL, RoweCC (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol69, 181–192.
ReiterK, NielsonKA, DurgerianS, WoodardJL, SmithJC, SeidenbergM, KellyDA, RaoSM (2017) Five-year longitudinal brain volume change in healthy elders at genetic risk for Alzheimer’s disease. J Alzheimers Dis55, 1363–1377.
27.
DowellNG, EvansSL, ToftsPS, KingSL, TabetN, RustedJM (2016) Structural and resting-state MRI detects regional brain differences in young and mid-age healthy APOE-e4 carriers compared with non-APOE-e4 carriers. NMR Biomed29, 614–624.
28.
VillemagneVL, BurnhamS, BourgeatP, BrownB, EllisKA, SalvadoO, SzoekeC, MacaulaySL, MartinsR, MaruffP, AmesD, RoweCC, MastersCL, AIBL Research Group (2013) Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease:A prospective cohort study. Lancet Neurol12, 357–367.
29.
JackCR, KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, TrojanowskiJQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol12, 207–216.
30.
BennettDA, SchneiderJA, WilsonRS, BieniasJL, ArnoldSE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol61, 378–384.
31.
IngelssonM, FukumotoH, NewellKL, GrowdonJH, Hedley-WhyteET, FroschMP, AlbertMS, HymanBT, IrizarryMC (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology62, 925–931.
32.
GiannakopoulosP, HerrmannFR, BussièreT, BourasC, KövariE, PerlDP, MorrisonJH, GoldG, HofPR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology60, 1495–1500.
33.
AshfordJW (2004) APOE genotype effects on Alzheimer’s disease: Onset and epidemiology. J Mol Neurosci23, 157–165.
34.
RaberJ, HuangY, AshfordJW (2004) APOE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging25, 641–650.
35.
KanekiyoT, XuH, BuG (2014) ApoE and Aβ in Alzheimer’s disease: Accidental encounters or partners?Neuron81, 740–754.
36.
YuL, BoylePA, LeurgansS, SchneiderJA, BennettDA (2014) Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging35, 819–826.
37.
MonsellSE, KukullWA, RoherAE, MaaroufCL, SerranoG, BeachTG, CaselliRJ, MontineTJ, ReimanEM (2015) Characterizing apolipoprotein E ɛ4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol72, 1124–1131.
ShinoharaM, KanekiyoT, YangL, LinthicumD, ShinoharaM, FuY, PriceL, Frisch-DaielloJL, HanX, FryerJD, BuG (2016) APOE2 eases cognitive decline during aging: Clinical and preclinical evaluations. Ann Neurol. doi: 10.1002/ana.24628
40.
ReimanEM, LangbaumJB, FleisherAS, CaselliRJ, ChenK, AyutyanontN, QuirozYT, KosikKS, LoperaF, TariotPN (2011) Alzheimer’s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis26, 321–329.
41.
RosesAD, SaundersAM, LutzMW, ZhangN, HaririAR, AsinKE, CrenshawDG, BudurK, BurnsDK, BrannanSK (2014) New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol14, 81–89.
